A Johns Hopkins vaccine targeting KRAS mutations safely triggered immune responses in 90% of participants, a breakthrough in pancreatic cancer prevention.
New oral drug daraxonrasib nearly doubled survival in metastatic pancreatic cancer patients, marking a breakthrough against one of the deadliest cancers.